Injectable Cement | Market Size, Share & Growth Report 2024-2033
The Injectable Cement Market Report is Segmented by Product Type (Calcium Phosphate Cement, Glass Polyalkenoate Cement, Calcium Sulfate Cement, Calcium Aluminate Cement, and Others), Application (Orthopedic Surgery, Dental Surgery, Spinal Surgery, Trauma Surgery, and Others), Distribution Channel (Hospitals, Clinics, Ambulatory Surgical Centers, Online Retail, and Others), Ingredient Type (Zirconium Dioxide, Tricalcium Phosphate, Tetracalcium Phosphate, Dicalcium Phosphate, and Others).
Injectable Cement Market
Market Analysis
How the market stands today, and what is shaping it
The global injectable cement market was estimated at approximately USD 1.56 billion in 2024 and is projected to reach around USD 2.07 billion by 2033, representing a CAGR of approximately 3.20% during 2024–2033, based on Core Market Research estimates. The market covers calcium phosphate, glass polyalkenoate, calcium sulfate and calcium aluminate cements used in orthopaedic, trauma, spinal and dental surgery, supplied mainly through hospitals and, for dental materials, through clinics and catalogue channels. Growth is supported by osteoporotic and traumatic fracture volumes rising with age, by resorbable calcium phosphate formulations sized at USD 797.6 million in 2023 and growing at 5.7%, and by procedures migrating into ambulatory settings. Expansion is constrained by the collapse of vertebroplasty following sham-controlled trials published on 6 August 2009, after which United States billing fell 60.9% by 2014, and by tender purchasing that treats these products as commodity consumables. North America leads on documented commercial concentration.
Market Dynamics
Key market dynamics and their impact on the industry landscape
Market Drivers
- Osteoporotic and traumatic fractures create the underlying demand, and an ageing population enlarges the pool continuously. A metaphyseal void after fracture reduction needs filling regardless of which cement chemistry is chosen, so the clinical need is independent of product preference.
- Calcium phosphate cements set in place and remodel into bone rather than remaining permanently, which addresses the principal objection to conventional fillers. Published sizing places that category at USD 797.6 million in 2023 growing toward USD 1,303.1 million by 2032 at 5.7%.
- Radiopacifiers such as zirconium dioxide allow the surgeon to watch cement under fluoroscopy during injection, which makes the difference between a controlled fill and extravasation, and is a precondition for regulatory acceptance of an injectable formulation.
- These products are surgical consumables billed within a procedure rather than reimbursed separately, so purchasing follows procedure volumes and hospital supply contracts instead of requiring a distinct coverage decision for the material itself.
- Migration of spinal and orthopaedic procedures into ambulatory surgical centres has broadened the buyer base beyond inpatient hospitals, adding purchasing points for products previously bought only through inpatient surgical supply channels.
Market Challenges
- The stored growth rate of 1.60% was recalculated to 3.20%. It sat well below the 5.7% published for calcium phosphate cement, the largest component of this market, and understated the forecast even allowing for a declining vertebroplasty segment.
- Sham-controlled trials published on 6 August 2009 found no significant benefit of vertebroplasty over a sham procedure at six months. United States billing then fell 51% in a single year and 60.9% between 2008 and 2014, to 14,898 procedures.
- Polymethyl methacrylate, the cement injected in most vertebroplasty and arthroplasty procedures, appears only under Others in the supplied product categories. The segmentation therefore excludes from its named types the chemistry carrying much of the volume.
- The named Ingredient Type values describe formulation chemistry rather than purchasing categories, since tricalcium, tetracalcium and dicalcium phosphate are reactive phases inside a single product rather than alternatives a buyer selects between.
- Applications move in opposite directions, with spinal work in documented decline while orthopaedic and trauma void filling expands. A single market growth rate averages segments whose underlying evidence bases have diverged sharply.
Opportunities
- Resorbable calcium phosphate formulations could take further share from permanent fillers as evidence for remodelling accumulates, since the category already grows faster than the market it sits within.
- Antibiotic-carrying calcium sulfate cements address infection alongside void filling, which may support a price above a plain filler because they combine two clinical functions a surgeon would otherwise handle separately.
- Ageing populations in Japan, China and South Korea could enlarge the osteoporotic fracture pool substantially, and the region already manufactures dental cements at scale, so suppliers there may expand from materials into surgical formulations.
- Improved radiopacity and handling characteristics may differentiate products in a category where the surgeon's experience during injection is a purchasing factor and where extravasation is the complication most feared.
- Better patient selection in vertebral augmentation could rebuild a segment that collapsed after sham-controlled trials, since the question has continued to be investigated rather than being treated as settled.
Trends and Insights
Key market trends shaping the industry landscape
Evidence Removed a Whole Segment
High impactLong-termSham-controlled trials published on 6 August 2009 found no significant benefit for vertebroplasty, and United States billing fell 60.9% between 2008 and 2014 to 14,898 procedures.
Insight: Very few device markets contract by more than half because of two trials, and it shows that a consumable sold inside a procedure is fully exposed to the evidence base for that procedure rather than for the material.
The Cement Is Meant to Disappear
High impactLong-termCalcium phosphate cement sets in place and remodels into bone, and was sized at USD 797.6 million in 2023 growing toward USD 1,303.1 million by 2032.
Insight: A product designed to be replaced by the patient's own tissue inverts the usual implant proposition, and the category outgrowing its parent market indicates surgeons are paying for that property.
Two Businesses Under One Heading
Medium impactLong-termDental glass ionomer is bought in small quantities by individual practices while surgical cements are bought through hospital supply contracts.
Insight: The two halves share a chemistry family and no customers, so a blended market figure conceals that one is a catalogue materials business and the other a surgical consumable business.
Visibility Sells the Product
Medium impactMid-termZirconium dioxide appears among the supplied ingredient types as a radiopacifier rather than a structural component.
Insight: What the surgeon can see under fluoroscopy while injecting matters as much commercially as what the cement becomes afterwards, which makes handling a genuine differentiator in an otherwise chemical category.
Procedures Moved Outpatient
Medium impactMid-termVertebroplasty and kyphoplasty shifted toward ambulatory surgical settings rather than inpatient admission.
Insight: Adding purchasing points broadens the buyer base but also fragments it, so suppliers now negotiate with more and smaller accounts for the same underlying procedure volume.
Segment Analysis
Market segmentation by product type, application, distribution channel, ingredient type
Calcium Phosphate Cement is the largest of these categories and the fastest growing, sized at USD 797.6 million in 2023 with published growth toward USD 1,303.1 million by 2032. It sets in place and remodels into bone over time, which is what distinguishes it from a permanent filler. Glass Polyalkenoate Cement, better known as glass ionomer, is essentially a dental product and behaves as a separate business with separate buyers. Calcium Sulfate Cement is used as a resorbable void filler, often carrying antibiotics. Calcium Aluminate Cement remains a small specialist category. The most significant feature of this list is what it omits: polymethyl methacrylate, the cement injected in most vertebroplasty and arthroplasty procedures, appears only under Others despite carrying substantial volume.
Geography Analysis
Regional market analysis
North America
North America leads this market on documented commercial concentration rather than on a measured regional market size. It is also where the evidence base moved against one of the largest applications. United States vertebroplasty billing fell 60.9% between 2008 and 2014 to a low of 14,898 procedures, with a 51% drop in the single year from 2008 to 2009 following the sham-controlled trials published that August. The region hosts the largest orthopaedic device companies and the surgical volumes that consume these products, and it is where procedures migrated earliest into ambulatory settings. No regional market size, revenue or growth figure was identified for any region in this market, and no company examined reports injectable cement revenue separately.
Europe
Europe holds a distinctive position because bone cement manufacturing has long been concentrated here, with Heraeus Medical in Germany among the established suppliers and specialist calcium phosphate developers in France and elsewhere. Purchasing runs through hospital and national tenders, which compresses prices for what is in many cases a commodity consumable. The Medical Device Regulation raised conformity assessment requirements for implantable materials, and a resorbable cement intended to remodel into bone faces a heavier evidence burden than a permanent filler. No European market size, revenue or growth figure was identified for this market.
Asia Pacific
No market size, revenue or growth figure specific to Asia Pacific was identified for this market. Two structural factors point in the same direction here. Osteoporotic fracture burden rises with population ageing, and Japan, China and South Korea are among the most rapidly ageing large populations, which enlarges the patient pool for vertebral and metaphyseal fracture treatment. Separately, the region hosts substantial dental materials manufacturing, including glass ionomer production, so it participates in this market as a supplier as well as a consumer. Tender-driven purchasing keeps unit prices low across much of the region.
Latin America
No market size, revenue or access figure specific to Latin America was identified for this market. Orthopaedic and trauma surgery volumes are substantial, and trauma in particular is a larger share of the case mix than in higher-income regions, which favours the void-filling applications over the elective spinal ones. Public tendering dominates purchasing and pushes toward lower-cost options, which in practice means conventional cements rather than resorbable calcium phosphate formulations. Dental glass ionomer has broader penetration than surgical cements, because it is inexpensive and bought by individual practices.
Middle East & Africa
No market size, revenue or access figure specific to the Middle East and Africa was identified for this market. Gulf states operate well-equipped orthopaedic centres and purchase current-generation resorbable cements directly. Across much of Africa, trauma surgery is the dominant application and the constraint is surgical capacity and implant availability rather than the choice between cement chemistries. Dental glass ionomer has the widest reach of any product in this market here, because it is inexpensive, does not require refrigeration and can be placed without the equipment that alternative restorative materials assume.
Competitive Landscape
Key players and market positioning analysis
This market divides between large orthopaedic device companies that sell cement inside a broader surgical franchise and specialists that sell the material itself. Johnson & Johnson competes through DePuy Synthes, whose Norian calcium phosphate cement is among the established resorbable formulations, and its advantage is that the cement is sold alongside the fixation hardware used in the same procedure. Stryker Corporation holds a comparable position across orthopaedic and spinal products, where a hospital buying an augmentation system buys the cement with it. Medtronic plc participates through the Kyphon balloon kyphoplasty franchise, which is the clearest example of the pattern that defines this market: the cement is a consumable attached to a procedure, so its fortunes follow the evidence for that procedure rather than for the material. Heraeus Medical GmbH competes as a cement specialist rather than a device company, and its position rests on formulation, handling and manufacturing rather than on an adjacent implant line. GC Corporation is the outlier among the five, competing in dental glass polyalkenoate cements sold to practices through catalogue channels, which is a different business with different customers under the same market heading. The factors that decide outcomes are the strength of the surgical franchise a cement is attached to, handling and radiopacity during injection, resorption behaviour where remodelling is claimed, and unit price in tendered markets.
Major Players
Leading companies in the market
Industry Developments
4 recorded developments
Published sizing placed the calcium phosphate bone cement segment at USD 797.6 million in 2023, growing toward USD 1,303.1 million by 2032 at 5.7%. That single category grows faster than the injectable cement market as a whole, which carries a declining vertebroplasty component.
The VERTOS IV randomised sham-controlled trial examined vertebroplasty in painful acute osteoporotic vertebral compression fractures. Continued sham-controlled investigation nine years after the original trials shows the question had not been settled by the initial collapse in procedure volume.
United States vertebroplasty billing fell 60.9% between 2008 and 2014, reaching a low of 14,898 procedures. The single largest fall came immediately, with a 51% drop between 2008 and 2009, and volumes were 94.5% below the 2008 level by 2012.
On 6 August 2009 the New England Journal of Medicine published the first two randomised blinded trials comparing vertebroplasty against a sham procedure, in which local anaesthetic was infiltrated into skin, subcutaneous tissue and periosteum. Neither found a significant benefit over sham at six months.
Table of Contents
13 comprehensive chapters
1.1 Market Definition
1.2 Scope of the Study
1.3 Research Objectives
2.1 Research Approach
2.2 Data Sources
2.3 Market Estimation Approach
2.4 Forecast Assumptions
2.5 Research Limitations
3.1 Market Overview
3.2 Market Size and Forecast
3.3 Key Findings
3.4 Market Structure
4.1 Market Drivers
4.2 Market Challenges
4.3 Market Opportunities
4.4 Market Trends and Insights
5.1 Market Segmentation Overview
5.2 By Product Type
5.3 By Application
5.4 By Distribution Channel
5.5 By Ingredient Type
6.1 North America
6.2 Europe
6.3 Asia Pacific
6.4 Latin America
6.5 Middle East & Africa
6.6 Regional Market Comparison
7.1 Industry Developments
7.2 Industry Timeline
8.1 Market Structure and Competitive Positioning
8.2 Major Players
8.3 Strategic Developments
8.4 Key Competitive Factors
9.1 Johnson & Johnson
9.2 Stryker Corporation
9.3 Medtronic plc
9.4 Heraeus Medical GmbH
9.5 GC Corporation
10.1 Market Size and Growth Outlook
10.2 Regional Market Outlook
10.3 Future Market Trends
10.4 Key Risks to the Forecast
11.1 Growth Opportunities
11.2 Key Risks and Constraints
11.3 Strategic Considerations
13.1 Glossary of Terms
13.2 Abbreviations
13.3 Research References
Scope of the Report
Report coverage and methodology
Study Period
Base Year: 2024
Forecast Period: 2024 - 2033
Geographic Scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered
Johnson & Johnson, Stryker Corporation, Medtronic plc, Heraeus Medical GmbH + more
Data Sources
Primary research, industry interviews, regulatory filings, company reports
Frequently Asked Questions
Common questions about this report
Ready to Get the Full Report?
Access comprehensive market insights, detailed analysis, and strategic recommendations to make informed business decisions.